Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Phase 1 Cancer Trials

Boston, Massachusetts

Phase 1 cancer trials in Boston, MA

178 Phase 1 cancer studies are recruiting participants at sites in Boston as of November 17, 2026, according to ClinicalTrials.gov. Phase 1 Cancer Trials can help you understand your options and connect with a study team.

Call (888) 927-9038
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

Boston at a glance

  • 178 studies are recruiting at a site in Boston.
  • By phase: Early Phase 1 (2), Phase 1 (84), Phase 1/2 (92).
  • By sponsor: industry (148), university, hospital or other (26), government (4).
  • By research area: Breast Cancer (61), Lung Cancer (55), Lymphoma (34), Prostate Cancer (13), Melanoma (8), Pancreatic Cancer (7).
  • Most recent update to one of these records: November 17, 2026.

Breast cancer studies recruiting in Boston

Basic details from each study's public record (the 30 most recently updated of 178). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer

    • Phase 1
    • Ages 18 and older
    • Female participants
    Sponsor
    Totus Medicines
    Study site
    Dana-Farber Cancer Institute
    Registry record
    NCT05683418 · updated
  2. A Phase 1/2 Study of IAM1363 in HER2 Cancers

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Iambic Therapeutics, Inc
    Study sites
    Dana Farber Cancer Institute · Massachusetts General Hospital
    Registry record
    NCT06253871 · updated
  3. Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Boehringer Ingelheim
    Study site
    Dana-Farber Cancer Institute
    Registry record
    NCT06324357 · updated
  4. Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Dana-Farber Cancer Institute ( Site 0050)
    Registry record
    NCT06686394 · updated
  5. Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

    • Phase 1
    • Ages 12 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Dana-Farber Cancer Institute
    Registry record
    NCT05372640 · updated
  6. Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemotherapy (Nab-Paclitaxel) Treatment in Patients With Advanced Triple-Negative Breast Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Dana-Farber Cancer Institute
    Registry record
    NCT05422794 · updated
  7. A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Stemline Therapeutics, Inc.
    Study sites
    Dana-Farber Cancer Institute · Massachusetts General Hospital Cancer Center
    Registry record
    NCT06638307 · updated
  8. Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    ORIC Pharmaceuticals
    Study site
    Dana Farber Cancer Institute
    Registry record
    NCT05315700 · updated
  9. A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

    • Phase 1
    • Ages 19 and older
    • All sexes
    Sponsor
    NiKang Therapeutics, Inc.
    Study site
    Dana Farber Cancer Institute
    Registry record
    NCT06586957 · updated
  10. A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    NiKang Therapeutics, Inc.
    Study site
    Dana-Farber Cancer Institute
    Registry record
    NCT07029399 · updated
  11. Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Genmab
    Study sites
    Dana Farber Cancer Institute · Massachusetts General Hospital
    Registry record
    NCT05579366 · updated
  12. A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Compass Therapeutics
    Study sites
    Beth Israel Deaconess Medical Center · Dana-Farber Cancer Institute
    Registry record
    NCT06150664 · updated
  13. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Massachusetts General Hospital
    Registry record
    NCT06465069 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in Boston, MA on ClinicalTrials.gov.

Lung cancer studies recruiting in Boston

  1. Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Vivace Therapeutics, Inc
    Study sites
    Dana-Farber Cancer Institute · Massachusetts General Hospital
    Registry record
    NCT04665206 · updated
  2. Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Institut de Recherches Internationales Servier
    Study site
    Dana-Farber Cancer Institute
    Registry record
    NCT05786924 · updated
  3. A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors

    • Phase 1
    • Ages 18 to 99
    • All sexes
    Sponsor
    Erasca, Inc.
    Study sites
    Dana Farber Cancer Institute · Massachusetts General Hospital (MG)
    Registry record
    NCT06983743 · updated
  4. A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    BioNTech SE
    Study site
    Dana-Farber Cancer Institute
    Registry record
    NCT07111520 · updated
  5. A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Bayer
    Study site
    Massachusetts General Hospital - Neurology
    Registry record
    NCT06914128 · updated
  6. A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Kestrel Therapeutics, Inc.
    Study site
    Mass General Brigham Cancer Institute at Massachusetts General Hospital
    Registry record
    NCT07458347 · updated
  7. A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Verastem, Inc.
    Study site
    Massachusetts General Hospital
    Registry record
    NCT07020221 · updated
  8. A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study sites
    Brigham and Women's Hospital · Dana-Farber Cancer Institute
    Registry record
    NCT07090499 · updated
  9. A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    TRIANA Biomedicines, Inc.
    Study sites
    Dana Farber Cancer Center · Massachusetts General Hospital
    Registry record
    NCT07491497 · updated
  10. A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    BlossomHill Therapeutics
    Study sites
    Beth Israel Deaconess Medical Center · Dana-Farber Cancer Institute · Massachusetts General Hospital
    Registry record
    NCT06706076 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in Boston, MA on ClinicalTrials.gov.

Prostate cancer studies recruiting in Boston

  1. A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors

    • Phase 1/2
    • Ages 18 and older
    • All sexes
    Sponsor
    Regeneron Pharmaceuticals
    Study site
    Massachusetts General Hospital
    Registry record
    NCT03972657 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in Boston, MA on ClinicalTrials.gov.

Melanoma studies recruiting in Boston

  1. A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)

    • Phase 1/2
    • From 6 months, up to 17 years
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Call for Information (Investigational Site 0026)
    Registry record
    NCT02332668 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in Boston, MA on ClinicalTrials.gov.

Lymphoma studies recruiting in Boston

  1. The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

    • Phase 1/2
    • Up to age 22
    • All sexes
    Sponsor
    PedAL BCU, LLC
    Study site
    Dana-Farber Cancer Institute
    Registry record
    NCT04726241 · updated
  2. A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

    • Phase 1/2
    • Ages 12 and older
    • All sexes
    Sponsor
    Nuvalent Inc.
    Study sites
    Dana Farber Cancer Institute · Massachusetts General Hospital
    Registry record
    NCT05384626 · updated
  3. A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

    • Phase 1/2
    • From 6 months, up to 30 years
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    Dana-Farber Cancer Institute
    Registry record
    NCT05533775 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in Boston, MA on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in Boston

  1. A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    Astellas Pharma Global Development, Inc.
    Study site
    Massachusetts General Hospital
    Registry record
    NCT07024615 · updated
  2. Testing the Safety and Tolerability of the Anti-cancer Drugs Trastuzumab Deruxtecan and Neratinib for Cancers With Changes in the HER2 Gene

    • Phase 1
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Dana-Farber Cancer Institute
    Registry record
    NCT05372614 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in Boston, MA on ClinicalTrials.gov.

Ask about studies near Boston

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 17, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 1, including early Phase 1 and combined Phase 1/2, as each study is coded in the registry.

Phase 1 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 927-9038

or send a short form

How should we reach you?

Call